These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
340 related articles for article (PubMed ID: 21054467)
1. A case of myeloid neoplasm associated with eosinophilia and KIAA1509-PDGFRβ responsive to combination treatment with imatinib mesylate and prednisolone. Wang JR; Yen CC; Gau JP; Hsiao LT; Liu CY; Pai JT; Tzeng CH; Teng HW J Clin Pharm Ther; 2010 Dec; 35(6):733-6. PubMed ID: 21054467 [TBL] [Abstract][Full Text] [Related]
2. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402 [TBL] [Abstract][Full Text] [Related]
3. Myeloid neoplasm with prominent eosinophilia and PDGFRA rearrangement treated with imatinib mesylate. Rathe M; Kristensen TK; Møller MB; Carlsen NL Pediatr Blood Cancer; 2010 Oct; 55(4):730-2. PubMed ID: 20589620 [TBL] [Abstract][Full Text] [Related]
4. [Idiopathic hypereosinophilic syndrome: toward a new molecular-targeted therapy and a new cytomorphological and molecular definition]. Moles MP; Landry J; Roche-Lestienne C; Godon A; Schmidt-Tanguy A; Gardembas M; Le Clech C; Verret JL; Zandecki M; Blanchet O Ann Biol Clin (Paris); 2005; 63(3):317-22. PubMed ID: 15951264 [TBL] [Abstract][Full Text] [Related]
5. KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32). Levine RL; Wadleigh M; Sternberg DW; Wlodarska I; Galinsky I; Stone RM; DeAngelo DJ; Gilliland DG; Cools J Leukemia; 2005 Jan; 19(1):27-30. PubMed ID: 15496975 [TBL] [Abstract][Full Text] [Related]
6. FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib. Wang LN; Pan Q; Fu JF; Shi JY; Jin J; Li JM; Hu J; Zhao WL; Chen Z; Chen SJ Chin Med J (Engl); 2008 May; 121(10):867-73. PubMed ID: 18706197 [TBL] [Abstract][Full Text] [Related]
17. Myeloproliferative hypereosinophilic syndrome presenting as cardiac failure and response to imatinib. Desai N; Morkhandikar S; Sahay R; Jijina F; Patil P Am J Ther; 2014; 21(2):e35-7. PubMed ID: 24603276 [TBL] [Abstract][Full Text] [Related]
18. [Glivek in the therapy of some forms of Ph- and bcr/abl-negative myeloproliferative diseases and a myeloproliferative variant of idiopathic hypereosinophilic syndrome]. Nemchenko IS; Khoroshko ND; Turkina AG; Vinogradova OIu; Sokolova MA; Abakumov EM; Semenova EA; Zakharova AV; Domracheva EV Ter Arkh; 2004; 76(7):87-90. PubMed ID: 15379136 [No Abstract] [Full Text] [Related]